(September 2020)
US tension with China is reaching new heights over the last few weeks. Not only are the two countries in an escalating trade war that has finally started to see China getting more assertive vis-a-vis Trump’s actions, but now Beijing and Washington are squaring off over TikTok. With trade relations between the countries devolving, Goldman says the best action investors can take is to invest in funds which have exposure to US onshoring efforts. Goldman’s thesis is that economic tension with China will lead to the onshoring of US supply lines, and that such a transition will benefit a handful of sectors. In particular, pharmaceuticals may do well as it is becoming very plausible that the US government might mandate that pharmaceutical drugs need to be made in the US. Additionally, automation and robotics companies stand to gain as the expense of reshoring US manufacturing leads to investments in automation.
(New York)
FINSUM + Magnifi: Pharmaceuticals are an interesting angle, but that would still be reliant on policy changes by the government. Robotics and automation funds seem like a safer bet as that transition is already under way.
{{cta(‘031ca73e-408c-41ef-9886-bfe7cd5553d7’)}}
Magnifi is changing the way we shop for investments, with the world’s first semantic search engine for finance that helps users discover, compare and buy investment products such as ETFs, mutual funds and stocks. As of August 2020, 75,000 users with $210 Billion in Assets Under Influence, has used Magnifi over 225,000 times. Try it for yourself today.
This blog is sponsored by Magnifi. The information and data are as of the publish date unless otherwise noted and subject to change. This material is provided for informational purposes only and should not be construed as individualized investment advice or an offer or solicitation to buy or sell securities tailored to your needs. This information covers investment and market activity, industry or sector trends, or other broad-based economic or market conditions and should not be construed as investment research or advice. Investors are urged to consult with their financial advisors before buying or selling any securities. Although certain information has been obtained from sources believed to be reliable, we do not guarantee its accuracy, completeness or fairness. Past performance is no guarantee of future results. This content may not be reproduced or distributed to any person in whole or in part without the prior written consent of Magnifi. [As a technology company, Magnifi provides access to tools and will be compensated for providing such access. Magnifi does not provide broker-dealer, custodian, investment advice or related investment services.]
